Related Experiment Video
Updated: Apr 18, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
A prospective observational study on the value of HPV E6/E7 oncoprotein immunocytochemistry for triaging HPV-positive
Zangyu Pan1,2, Qi Sun1,2, Yixiao Wang1,2
1Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China.
Background:
While human papillomavirus testing has become the primary screening modality for cervical cancer prevention, its implementation necessitates supplementary triage strategies. The viral oncoproteins E6 and E7, serving as primary mediators of high-risk HPV (hrHPV)-induced carcinogenesis, emerge as viable candidates for this risk stratification. We aimed to examine the clinical diagnostic performance of HPV E6/E7 immunocytochemical (ICC) assay in exfoliated cervical cells samples, to investigate the feasibility of using it as a potential biomarker in clinical triage algorithms for hrHPV-positive populations.
Methods:
We prospectively collected and analyzed 1,005 hrHPV-positive cases from Beijing Obstetrics and Gynecology Hospital, Capital Medical University during September 2023 and March 2025. The diagnostic and triaging performance of HPV E6/E7 ICC assay were evaluated by sensitivity, specificity, positive predictive values, negative predictive values and operating characteristic curve.
Results:
When used to detect CIN2+, the sensitivity of HPV E6/E7 ICC detection is (0.88, 95% CI: 0.82-0.92), which is better than that of cytological detection (0.609, 95% CI: 0.53-0.67), χ 2 = 26.23, p < 0.05; the NPV of. HPV E6/E7 ICC detection is (0.95, 95% CI: 0.92-0.97), which is better than that of cytological detection (0.85, 95% CI: 0.82-0.88), χ 2 = 38.14, p < 0.05. When the HPV typing test result is 16/18+,the sensitivity of HPV E6/E7 ICC detection is (0.93, 95% CI:0.86-0.96), which is better than that of cytological detection (0.61, 95% CI:0.52-0.70), χ 2 = 33.47, p < 0.05; the NPV of HPV E6/E7 ICC detection is (0.940, 95% CI:0.89-0.97), which is better than that of cytological detection (0.81, 95% CI:0.75-0.85), χ 2 = 13.84, p < 0.05. When the HPV typing test result is other hrHPV type, the sensitivity of HPV E6/E7 ICC detection is (0.81, 95% CI:0.71-0.89), which is better than that of cytological detection (0.75, 95% CI:0.64-0.84), χ 2 = 0.914, p = 0.339; the NPV of HPV E6/E7 ICC detection is (0.95, 95% CI:0.92-0.97), which is better than that of cytological detection (0.91, 95% CI:0.86-0.94), χ 2 = 4.29, p = 0.038.
Conclusion:
HPV E6/E7 ICC assay with high-sensitivity feature may be potential new biomarkers for hrHPV positive women. In addition, its triaging performance is better than that of cytology.
More Related Videos
10:26RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
Published on: March 11, 2014
13:41Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012